Karius
PrivateLast Round
Series C
May 2, 2024
Est. Valuation
$700M
Total Funding Raised
$350.27M
Company Overview
Karius operates in Healthcare & Life Sciences and is based in Redwood City, California. Its latest recorded funding round was a Series C round in May 2024.
Karius is a biotechnology company that provides genomic testing for infectious diseases by analyzing microbial DNA from blood samples to assist physicians in making rapid treatment decisions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Medical AI, Healthcare Analytics
Business Model
B2B
Customer Profile
Usage-Based SaaS, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Karius Comparables
Compare Karius with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Delve Bio | 76% | |
| Illumina, Inc. | 76% | |
| Vision Medicals | 75% |
For institutional investors. Book with your work email.
Karius Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | May 2, 2024 | ||||
| Series B | Feb 24, 2020 | ||||
| Debt | Nov 29, 2018 | ||||
| Series A | Aug 7, 2017 | ||||
| Seed | Oct 20, 2014 | ||||
Seed | Sep 1, 2014 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Karius Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SoftBank Investment Advisers | Series C, Series B |
| Waycross Ventures | Series C |
| Khosla Ventures | Series B, Series A, Series C |
| S28 Capital | Seed, Series A |
| Innovation Endeavors | Series C, Seed, Series A |
| SoftBank Group | Series C, Series B |
| 5AM Ventures | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2025
Karius Focus BAL test identifies 500 pathogens from BAL fluid.
- Oct 1, 2025
Karius Spectrum identifies over 1,000 pathogens from a single blood sample.
For institutional investors. Book with your work email.
Karius Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Karius's valuation, stock price, and market status.
Is Karius a public or private company?
Karius is a private company.
What is the current stock price of Karius?
Karius is a private company, so its shares have no public market price. Caplight tracks Karius's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Karius worth (valuation)?
Karius's valuation is estimated at $700.0M based on funding round data.
Can I buy Karius stock?
Karius shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Karius's last funding round?
Karius's most recent funding round was Series C on May 2, 2024.
Who are the main investors in Karius?
Key investors in Karius include SoftBank Investment Advisers, Khosla Ventures, S28 Capital, SoftBank Group, 5AM Ventures.
Will Karius IPO soon?
No public IPO plans have been announced for Karius.
How can I track Karius secondary market activity?
Caplight tracks bids, offers, and trades in Karius's shares on secondary markets.